Menu

Cancer Geneticist Quits After Harassment Allegations

Accusations that Nazneen Rahman bullied employees at the Institute of Cancer Research in the U.K. stretch back 12 years.

Jul 17, 2018
Kerry Grens
SCREEN SHOT FROM YOUTUBE, THEICRUK

Following numerous allegations that she harassed fellow employees, Nazneen Rahman, a cancer geneticist at the Institute of Cancer Research in the U.K., will leave her post come October, The Guardian reports. Rahman had already been on administrative leave since last November.

Dozens of colleagues signed a letter last year describing bullying by Rahman. “I really had a lack of confidence in my own abilities” because of Rahman’s mistreatment, one person tells The Guardian.

The Institute of Cancer Research (ICR) commissioned an independent investigation after learning of the allegations, and when Rahman was presented with the findings, she decided to quit, ICR tells The Guardian in a statement.

“I am sorry the group feel this way,” Rahman tells The Guardian. “I want to make it clear that following the investigation there were no disciplinary findings against me. And the decision to resign was mine and mine alone.”

Nazneen’s research focused on genetic predispositions to cancer, and she has been the leader of the Division of Genetics and Epidemiology at the ICR.

November 2018

Intelligent Science

Wrapping our heads around human smarts

Marketplace

Sponsored Product Updates

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC’s Genomics division announced it is transforming its branding under LGC, Biosearch Technologies, a unified portfolio brand integrating optimised genomic analysis technologies and tools to accelerate scientific outcomes.

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN Ltd are pleased to announce the commercial licensing of CRISPR-Cas9 gene-editing technology from Broad Institute of MIT and Harvard in the USA, to develop human cell disease models to support preclinical metabolic disease therapeutic programmes.

Thermo Fisher Scientific: Freezers for Biological Samples

Thermo Fisher Scientific: Freezers for Biological Samples

Fluctuations in temperature can reduce the efficacy, decompose, or shorten the shelf life of biologics. Therefore, it is important to store biologics at the right temperature using standardized protocols.